首页 > 市场调查报告书 > 製药

癌症呼吸器

2030 年欧洲肺癌治疗市场预测 - 区域分析 - 按治疗类型、适应症和最终用户

市场调查报告书

商品编码

1494406

2030 年欧洲肺癌治疗市场预测 - 区域分析 - 按治疗类型、适应症和最终用户

Europe Lung Cancer Therapy Market Forecast to 2030 - Regional Analysis - By Therapy Type, Indication, and End User

出版日期: 2024年03月14日 | 出版商:

The Insight Partners | 英文 92 Pages | 订单完成后即时交付

价格

简介目录图表

2022年欧洲肺癌治疗市值为991966万美元，预计2030年将达2554874万美元；预计2022年至2030年复合年增长率为12.6%。

政府肺癌筛检和治疗措施推动欧洲肺癌治疗市场

据强生公司发表的文章称，肺癌是全球癌症死亡的主要原因，而且通常在晚期才被发现。在早期阶段，肺癌患者没有明显的症状，因此，在近50%的检测病例中，癌症已达到转移阶段。针对肺癌的严重性，各国政府纷纷推出鼓励肺癌早期发现、早期筛检、早期治疗的措施。欧洲卫生联盟推出的「战胜癌症计画」旨在透过专注于肺癌患者的预防、治疗和照护来解决整个疾病途径。因此，各国政府为肺癌患者的早期检测和适当治疗所采取的措施激增，推动了欧洲肺癌治疗市场的成长。

欧洲肺癌治疗市场概况

根据2022年6月发表在《胸腔肿瘤学杂誌》上的一篇题为「德国的肺癌」的文章，癌症是德国第二大常见死因之一，占所有死亡的25%。男性和女性的年龄标化发生率分别为52.1%和32.7%（每10万人），肺癌在男性中排名第二，在女性中排名第三（分别占所有新诊断癌症的13.3%和9.4% ）。癌症诊断的平均年龄为70岁（男性）和69岁（女性）； 52% 的患者处于 IV 期。由于吸烟习惯的长期变化，自 20 世纪 90 年代以来，女性和男性的发病率趋同。目前，德国有四分之一的男性 (27.0%) 和五分之一的女性 (20.8%) 经常吸烟。

德国国家癌症计画指定器官癌症中心（肺癌中心）、肿瘤中心和综合癌症中心在德国提供一般肿瘤护理。截至2020年，全国79家机构、64家肺癌中心获得认证。德国肺癌发病率的上升和肺癌中心数量的增加正在推动市场的成长。

欧洲肺癌治疗市场收入及 2030 年预测（百万美元）

欧洲肺癌治疗市场细分

欧洲肺癌治疗市场根据治疗类型、适应症、最终用户和国家进行细分。

根据治疗类型，欧洲肺癌治疗市场分为非侵入性治疗和微创治疗。到2022年，非侵入性细分市场将占更大份额。

有迹象表明，欧洲肺癌治疗市场分为非小细胞肺癌和小细胞肺癌。 2022 年，非小细胞肺癌细分市场将占据更大份额。

依最终用户划分，欧洲肺癌治疗市场分为医院、肿瘤诊所、研究中心等。 2022 年，医院领域占最大份额。

根据国家/地区，欧洲肺癌治疗市场分为德国、英国、法国、义大利、西班牙、俄罗斯和欧洲其他地区。 2022年，德国在欧洲肺癌治疗市场占据主导地位。

Medtronic Plc、RF Medical Co Ltd、Johnson & Johnson、Merck KGaA、Sun Pharmaceutical Industries Ltd、Bioventus Inc、Olympus Corp、Meiji Seika Pharma Co Ltd 和 Advanz Pharma Corp 是欧洲肺癌治疗市场上的一些领先公司。

According to an article published by Johnson & Johnson, lung cancer is a leading cause of cancer mortality in the world, and it is generally detected in the later stages. In the initial stages, people with lung cancer show no prominent symptoms, and therefore, in almost 50% of the detected cases, cancer has already reached the metastasis stage. In response to the seriousness of this condition, governments of various countries are focusing on introducing initiatives for encouraging early detection and screening, followed by providing early treatment for lung cancer. The Beating Cancer Plan introduced by the European Health Union aims to tackle the entire disease pathway by focusing on prevention, treatment, and care of lung cancer patients. Thus, an upsurge in initiatives taken by governments for the early detection and proper treatment of lung cancer patients fuels the growth of the Europe lung cancer therapy market.

Europe Lung Cancer Therapy Market Overview

According to an article titled "Lung Cancer in Germany," published in the Journal of Thoracic Oncology in June 2022, cancer is among the second most frequent cause of death in Germany, accounting for 25% of all deaths. With an age-standardized incidence rate of 52.1% and 32.7% (per 100,000) in men and women, respectively, lung cancer ranks second in men and third in women (accounting for 13.3% and 9.4% of all newly diagnosed cancers, respectively). The average age of cancer diagnosis is 70 years (men) and 69 years (women); 52% of all patients present with stage IV. The incidence rates in women and men have converged since the 1990s because of long-term changes in smoking habits. Currently, every fourth man (27.0%) and every fifth woman (20.8%) in Germany smokes regularly.

The German National Cancer Plan designates organ cancer centers (lung cancer centers), oncology centers, and comprehensive cancer centers to offer general oncologic care in Germany. As of 2020, 64 lung cancer centers at 79 institutions were certified nationwide. Rise in the incidence of lung cancer and an increase in the number of lung cancer centers across Germany are fueling the growth of the market.

Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Million)

Europe Lung Cancer Therapy Market Segmentation

The Europe lung cancer therapy market is segmented based on therapy type, indication, end user, and country.

Based on therapy type, the Europe lung cancer therapy market is bifurcated into noninvasive and minimally invasive. The noninvasive segment held a larger share in 2022. The minimally invasive segment is further subsegmented into radiofrequency ablation, microwave ablation, thermal ablation, cryoablation, chemical ablation, photodynamic ablation, and others.

By indication, the Europe lung cancer therapy market is bifurcated into non-small cell lung cancer and small cell lung cancer. The non-small cell lung cancer segment held a larger share in 2022.

By end user, the Europe lung cancer therapy market is segmented into hospitals, oncology clinics, research centers, and others. The hospitals segment held the largest share in 2022.

Based on country, the Europe lung cancer therapy market is segmented into Germany, the UK, France, Italy, Spain, Russia, and the Rest of Europe. Germany dominated the Europe lung cancer therapy market in 2022.

Medtronic Plc, RF Medical Co Ltd, Johnson & Johnson, Merck KGaA, Sun Pharmaceutical Industries Ltd, Bioventus Inc, Olympus Corp, Meiji Seika Pharma Co Ltd, and Advanz Pharma Corp are some of the leading companies operating in the Europe lung cancer therapy market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Europe Lung Cancer Therapy Market, by Country

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe Lung Cancer Therapy Market - Key Industry Dynamics

4.1 Market Drivers:
- 4.1.1 Increase in Cases of Lung Cancer
- 4.1.2 Government Initiatives for Screening and Treatment of Lung Cancer
4.2 Market Restraints
- 4.2.1 High Cost of Lung Cancer Therapy
4.3 Market Opportunities
- 4.3.1 Rising Number of Lung Cancer Therapy in Clinical Trials
4.4 Future Trends
- 4.4.1 Growing Demand for Targeted Therapy
4.5 Impact Analysis:

5. Lung Cancer Therapy Market - Europe Market Analysis

5.1 Europe Lung Cancer Therapy Market Revenue (US$ Mn), 2020 - 2030

6. Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

6.1 Overview
6.2 Europe Lung Cancer Therapy Market Revenue Share, by Therapy Type, 2022 & 2030 (%)
6.3 Non-Invasive Therapy
- 6.3.1 Overview
- 6.3.2 Non-Invasive Therapy: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Minimally Invasive
- 6.4.1 Overview
- 6.4.2 Minimally Invasive: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- 6.4.3 Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)

7. Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by Indication

7.1 Overview
7.2 Europe Lung Cancer Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
7.3 Non-Small Cell Lung Cancer
- 7.3.1 Overview
- 7.3.2 Non-Small Cell Lung Cancer: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Small Cell Lung Cancer
- 7.4.1 Overview
- 7.4.2 Small Cell Lung Cancer: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by End User

8.1 Overview
8.2 Europe Lung Cancer Therapy Market Revenue Share, by End User, 2022 & 2030 (%)
8.3 Hospitals
- 8.3.1 Overview
- 8.3.2 Hospitals: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Oncology Clinics
- 8.4.1 Overview
- 8.4.2 Oncology Clinics: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Research Centers
- 8.5.1 Overview
- 8.5.2 Research Centers: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Lung Cancer Therapy Market - Country Analysis

9.1.1 Europe Lung Cancer Therapy Market, by Country
- 9.1.1.1 UK
  - 9.1.1.1.1 Overview
  - 9.1.1.1.2 UK: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.1.3 UK: Europe Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.1.3.1 UK: Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.1.4 UK: Europe Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.1.5 UK: Europe Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 9.1.1.2 Germany
  - 9.1.1.2.1 Overview
  - 9.1.1.2.2 Germany: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.2.3 Germany: Europe Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.2.3.1 Germany: Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.2.4 Germany: Europe Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.2.5 Germany: Europe Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 9.1.1.3 France
  - 9.1.1.3.1 Overview
  - 9.1.1.3.2 France: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.3.3 France: Europe Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.3.3.1 France: Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.3.4 France: Europe Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.3.5 France: Europe Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 9.1.1.4 Italy
  - 9.1.1.4.1 Overview
  - 9.1.1.4.2 Italy: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.4.3 Italy: Europe Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.4.3.1 Italy: Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.4.4 Italy: Europe Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.4.5 Italy: Europe Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 9.1.1.5 Spain
  - 9.1.1.5.1 Overview
  - 9.1.1.5.2 Spain: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.5.3 Spain: Europe Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.5.3.1 Spain: Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.5.4 Spain: Europe Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.5.5 Spain: Europe Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 9.1.1.6 Russia
  - 9.1.1.6.1 Overview
  - 9.1.1.6.2 Russia: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.6.3 Russia: Europe Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.6.3.1 Russia: Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.6.4 Russia: Europe Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.6.5 Russia: Europe Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 9.1.1.7 Rest of Europe
  - 9.1.1.7.1 Overview
  - 9.1.1.7.2 Rest of Europe: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
  - 9.1.1.7.3 Rest of Europe: Europe Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 9.1.1.7.3.1 Rest of Europe: Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
  - 9.1.1.7.4 Rest of Europe: Europe Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
  - 9.1.1.7.5 Rest of Europe: Europe Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)

10. Lung Cancer Therapy Market - Industry Landscape

10.1 Overview
10.2 Growth Strategies in Europe Lung Cancer Therapy Market
10.3 Inorganic Growth Strategies
- 10.3.1 Overview
10.4 Organic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Medtronic Plc
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 RF Medical Co Ltd
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Johnson & Johnson
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Merck KGaA
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Sun Pharmaceutical Industries Ltd
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Bioventus Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Olympus Corp
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Meiji Seika Pharma Co Ltd
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Advanz Pharma Corp
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms

简介目录图表

List Of Tables

Table 1. Europe Lung Cancer Therapy Market Segmentation
Table 2. Europe Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 3. UK: Europe Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 4. UK: Europe Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 5. UK: Europe Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 6. UK: Europe Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 7. Germany: Europe Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 8. Germany: Europe Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 9. Germany: Europe Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 10. Germany: Europe Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 11. France: Europe Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 12. France: Europe Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 13. France: Europe Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 14. France Europe Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 15. Italy Europe Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 16. Italy: Europe Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 17. Italy: Europe Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 18. Italy: Europe Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 19. Spain: Europe Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 20. Spain: Europe Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 21. Spain: Europe Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 22. Spain: Europe Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 23. Russia: Europe Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 24. Russia: Europe Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 25. Russia: Europe Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 26. Russia: Europe Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 27. Rest of Europe: Europe Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 28. Rest of Europe: Europe Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 29. Rest of Europe: Europe Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 30. Rest of Europe: Europe Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 31. Recent Inorganic Growth Strategies in the Europe Lung Cancer Therapy Market
Table 32. Recent Organic Growth Strategies in Europe Lung Cancer Therapy Market
Table 33. Glossary of Terms, Europe Lung Cancer Therapy Market

List Of Figures

Figure 1. Europe Lung Cancer Therapy Market Segmentation, By Country
Figure 2. Europe Lung Cancer Therapy Market - Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Europe Lung Cancer Therapy Market Revenue (US$ Mn), 2020 - 2030
Figure 5. Europe Lung Cancer Therapy Market Revenue Share, by Therapy Type, 2022 & 2030 (%)
Figure 6. Non-Invasive Therapy: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Minimally Invasive: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Europe Lung Cancer Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
Figure 9. Non-Small Cell Lung Cancer: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Small Cell Lung Cancer: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Europe Lung Cancer Therapy Market Revenue Share, End User, 2022 & 2030 (%)
Figure 12. Hospitals: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Oncology Clinics: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Research Centers: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Others: Europe Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Europe Lung Cancer Therapy Market, by Key Country - Revenue, 2022 (US$ Million)
Figure 17. Europe Lung Cancer Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 18. UK: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 19. Germany: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 20. France: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. Italy: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Spain: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. Russia: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 24. Rest of Europe: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 25. Growth Strategies in Europe Lung Cancer Therapy Market